Tarsier Pharma's planned July 2026 NYSE American listing under ticker TARX, sized at $45-50 million with an implied post-IPO market cap near $294-299 million at the $8-10 share range, failed to proceed as scheduled. With the current date in mid-August 2026 and no updated F-1 amendments, pricing confirmations, or trading debut, trader consensus has coalesced around the 98.6% implied probability of no IPO before September 2026. This reflects standard biotech IPO headwinds, including clinical-stage execution risk on the Phase 3 Tarsier-04 trial and muted small-cap risk appetite amid prevailing interest-rate and equity-volatility conditions. A near-term reversal would require fresh SEC filings, a revised offering timeline, or positive pivotal data catalysts strong enough to reopen the window before the resolution cutoff.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoNo IPO before September 2026 98.4%
$400M-$450M 2.8%
$350M-$400M 1.7%
<$250M <1%
$15,167 Wol.
$15,167 Wol.
Jul 9, 2026
<$250M
<1%
$250M-$300M
<1%
$300M-$350M
<1%
$350M-$400M
2%
$400M-$450M
3%
>$450M
<1%
No IPO before September 2026
98%
No IPO before September 2026 98.4%
$400M-$450M 2.8%
$350M-$400M 1.7%
<$250M <1%
$15,167 Wol.
$15,167 Wol.
Jul 9, 2026
<$250M
$957 Wol.
<1%
$250M-$300M
$979 Wol.
<1%
$300M-$350M
$561 Wol.
<1%
$350M-$400M
$561 Wol.
2%
$400M-$450M
$349 Wol.
3%
>$450M
$680 Wol.
<1%
No IPO before September 2026
$11,080 Wol.
98%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's planned July 2026 NYSE American listing under ticker TARX, sized at $45-50 million with an implied post-IPO market cap near $294-299 million at the $8-10 share range, failed to proceed as scheduled. With the current date in mid-August 2026 and no updated F-1 amendments, pricing confirmations, or trading debut, trader consensus has coalesced around the 98.6% implied probability of no IPO before September 2026. This reflects standard biotech IPO headwinds, including clinical-stage execution risk on the Phase 3 Tarsier-04 trial and muted small-cap risk appetite amid prevailing interest-rate and equity-volatility conditions. A near-term reversal would require fresh SEC filings, a revised offering timeline, or positive pivotal data catalysts strong enough to reopen the window before the resolution cutoff.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Rynek otwarty: Jul 7, 2026, 9:12 AM ET
Wolumen
$15,167Data zakończenia
Jul 9, 2026Rynek otwarty
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's planned July 2026 NYSE American listing under ticker TARX, sized at $45-50 million with an implied post-IPO market cap near $294-299 million at the $8-10 share range, failed to proceed as scheduled. With the current date in mid-August 2026 and no updated F-1 amendments, pricing confirmations, or trading debut, trader consensus has coalesced around the 98.6% implied probability of no IPO before September 2026. This reflects standard biotech IPO headwinds, including clinical-stage execution risk on the Phase 3 Tarsier-04 trial and muted small-cap risk appetite amid prevailing interest-rate and equity-volatility conditions. A near-term reversal would require fresh SEC filings, a revised offering timeline, or positive pivotal data catalysts strong enough to reopen the window before the resolution cutoff.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Wolumen
$15,167Data zakończenia
Jul 9, 2026Rynek otwarty
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma's planned July 2026 NYSE American listing under ticker TARX, sized at $45-50 million with an implied post-IPO market cap near $294-299 million at the $8-10 share range, failed to proceed as scheduled. With the current date in mid-August 2026 and no updated F-1 amendments, pricing confirmations, or trading debut, trader consensus has coalesced around the 98.6% implied probability of no IPO before September 2026. This reflects standard biotech IPO headwinds, including clinical-stage execution risk on the Phase 3 Tarsier-04 trial and muted small-cap risk appetite amid prevailing interest-rate and equity-volatility conditions. A near-term reversal would require fresh SEC filings, a revised offering timeline, or positive pivotal data catalysts strong enough to reopen the window before the resolution cutoff.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania